ORIGINAL RESEARCH PAPER

Pathology

KEY WORDS: Precision oncology, Chemotherapy sensitivity, DNA polymerase epsilon mutations, immune checkpoint inhibitors in endometrial cancer.

# AN IN-DEPTH ANALYSIS OF POLE ULTRAMUTATED ENDOMETRIAL CARCINOMA- REVIEW

**Rushang Dave** Assistant Professor, Department of Pathology, Shantabaa Medical College & General Hospital, Amreli.

**Parth Goswami** Assistant Professor, Department of Pathology, AIIMS, Rajkot.

**Gyanendra Singh** Assistant Professor, Department of Pathology, AIIMS, Rajkot.

**Vaishali Belani** Senior Resident, Department of Pathology, Shantabaa Medical College & General Hospital, Amreli.

**ABSTRACT**

POLE ultramutated endometrial carcinoma is characterized by a unique genetic profile with a high mutation burden due to alterations in the polymerase epsilon (POLE) gene. This review explores the distinctive clinicopathological features, prognosis, and therapeutic implications of this rare subset of endometrial cancer. POLE mutations confer a hypermutated state that may enhance immunogenicity and improve patient outcomes compared to other endometrial carcinoma variants. This type of carcinoma typically shows favorable prognostic factors, including reduced rates of myometrial invasion and lymphovascular space involvement, leading to better overall survival and disease-specific outcomes. The review also discusses the potential for targeted immunotherapeutic strategies, leveraging the high mutational load to improve response rates to treatment. Future challenges include the need for precise diagnostic tools to identify POLE mutation status accurately and the exploration of novel therapeutic avenues that could further enhance the management of patients with this promising yet challenging form of endometrial carcinoma.

## INTRODUCTION:

Endometrial carcinoma is the most common gynecologic malignancy in developed countries, with its incidence rising in tandem with increasing life expectancy and obesity rates[1]. Traditionally, endometrial carcinomas have been categorized into Type I and Type II based on their histopathological and molecular characteristics, with each type having distinct etiologies, treatment responses, and prognoses[2]. Among these, POLE (polymerase epsilon) ultramutated endometrial carcinomas represent a novel and distinct subgroup identified through advanced genomic sequencing techniques[3].

## PATHOGENESIS:

The POLE gene encodes the catalytic subunit of DNA polymerase epsilon, a key enzyme involved in DNA replication and repair[4]. Mutations in POLE, particularly those leading to an ultramutated phenotype, are characterized by an exceptionally high number of DNA replication errors, resulting in a significant increase in the overall mutational burden of the tumors. This hypermutated state is thought to contribute to the development and progression of cancer through the accumulation of mutations in various oncogenes and tumor suppressor genes[5].

Clinically, POLE ultramutated endometrial carcinomas are noteworthy for their distinct biological behavior and prognostic implications. Patients with these tumors generally present with a favorable prognosis, largely due to the heightened immunogenicity conferred by the high mutational load, which may stimulate a more effective immune response against the tumor[6]. This feature also opens new avenues for therapeutic interventions, particularly with immunotherapeutic agents, which have shown promise in preliminary studies[7].

### Classification

The classification of endometrial carcinomas into Type I and Type II is based on both clinical behavior and molecular pathology. Type I carcinomas, typically hormone-dependent and endometrioid, are often associated with a background of hyperestrogenism and exhibit mutations in PTEN, PIK3CA, KRAS, and beta-catenin. In contrast, Type II carcinomas, which include serous and clear cell carcinomas, are generally hormone-independent and show a higher degree of genomic instability and poorer outcomes[1].

POLE ultramutated tumors, although less common, represent a unique category. They do not fit neatly into the traditional Type I and Type II classification because of their distinct mutation profile and clinical behavior. Instead, they are characterized by their genetic signature—mutations in the exonuclease domain of the POLE gene, which confer a high mutational load. This mutational profile is associated with a robust immunogenic response due to the creation of numerous neoantigens, which are targets for the immune system[3].

Clinically, this translates into a prognosis that is typically more favorable than that seen in other forms of endometrial cancer, with studies indicating lower rates of lymph node metastasis and a higher overall survival rate[2]. This distinct subgroup challenges the traditional dichotomy of endometrial carcinoma classification and suggests a potential for personalized therapeutic strategies, particularly leveraging immunotherapeutic approaches[6].

### Clinicopathological Features

The clinicopathological features of POLE ultramutated endometrial carcinoma are markedly distinct from other types of endometrial cancer due to the unique mutational profile of the POLE gene. This subset of tumors is characterized by a remarkably high mutation burden, which influences both the pathology and the clinical outcomes of the disease[8].

### Histological Characteristics

POLE ultramutated tumors typically exhibit specific histological features such as prominent nucleoli, increased nuclear atypia, and abundant mitotic figures. These features reflect the hypermutator phenotype, which results from defects in the proofreading function of the polymerase epsilon enzyme. Despite these aggressive histological features, POLE ultramutated tumors often have a paradoxically indolent clinical course, potentially due to the heightened immune response elicited by the high neoantigen load produced by the numerous mutations[4].

### Immunogenicity

The high mutational load in POLE ultramutated tumors is believed to contribute to their immunogenicity. This increased immunogenicity is thought to be a key factor in the favorable prognosis observed in these patients. Tumors with

POLE mutations often infiltrate with lymphocytes, suggesting an active immune environment that may be more amenable to immune checkpoint blockade therapy. This aspect is currently under investigation in several clinical trials aiming to determine the efficacy of immunotherapy in this distinct subgroup[3,9].

**Prognostic Implications**

Clinically, patients with POLE ultramutated endometrial carcinoma generally present with a better prognosis compared to those with other genetic subtypes of endometrial cancer. Studies have consistently reported prolonged survival and lower recurrence rates in patients with these mutations, even in cases where traditional prognostic indicators would suggest a poorer outcome. This anomaly can be attributed to the effective immune surveillance in these tumors, highlighting the importance of genetic profiling in the management of endometrial carcinoma[10].

**Molecular Characteristics**

At the molecular level, the mutations in the POLE gene lead to a dysfunctional DNA polymerase that is unable to correctly proofread DNA, thus increasing the rate of mutagenesis. This biochemical pathway not only results in the cancer phenotype but also makes these cells targets for immune-mediated destruction due to the presentation of novel antigens that are recognized as non-self by the immune system[7].

**Treatment And Management**

The management of POLE ultramutated endometrial carcinoma generally follows the standard protocols for endometrial cancer, including surgery, radiation, and chemotherapy. However, the high mutational burden may offer novel therapeutic targets, suggesting potential benefits from immunotherapy. Current clinical trials are exploring the efficacy of checkpoint inhibitors, which hold promise for improving outcomes in this subgroup[3].

**Challenges And Future Directions**

While the prognosis for patients with POLE ultramutated endometrial carcinoma is generally favorable, challenges remain, particularly in terms of accurately identifying and categorizing these tumors in clinical practice. Future research is necessary to better understand the underlying mechanisms driving the high mutation rates and to explore targeted therapies that could exploit the unique tumor microenvironment of these cancers[10].

**REFERENCES**

1. Couturier J. Uterus: Endometrial carcinoma [Internet]. Paris: Pathologica; 2011 [cited 2024 Apr 10]. Available from: https://dx.doi.org/10.4267/2042/37519
2. Nieberg RK, Hirschowitz S. Malignant endometrial pathology. Curr Opin Obstet Gynecol. 1992 Aug;4(4):492-497.
3. Koh W, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2018 Feb;16(2):170-199. Available from: https://jnccn.org/downloadpdf/journals/jnccn/16/2/article-p170.pdf
4. Shiozawa T, Yamazaki T, Noguchi H, Fukuta T. Clinicopathological Study of Endometrial Carcinoma [Internet]. Sapporo: Hokkaido University Medical Library; 1986 [cited 2024 Apr 10]. Available from: https://www.hokudai.ac.jp
5. Sato Y, Hida S, Inagaki M, Tsutsumi H, Hirota Y, Hongo J, et al. A Clinicopathologic Study of Endometrial Carcinomas with Argyrophil Cell. Acta Pathol Jpn. 1984 Nov;34(11):1669-1678.
6. Wiesel O, Kessous R, Dreiher J, Meirovitz M, Davidesko S, Samueli B, et al. Ambiguous high-grade endometrial carcinomas – an analysis of clinicopathologic factors and prognostic outcomes [Internet]. Int J Gynecol Cancer. 2023 Sep;33(Suppl 3):A151. Available from: https://dx.doi.org/10.1136/ijgc-2023-esgo.311
7. Rabban JT, Gilks CB, Malpica A, Matías-Guiu X, Mittal K, Mutter GL, et al. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists [Internet]. Am J Surg Pathol. 2018 Dec;42(12):e49-e65. Available from: https://dx.doi.org/10.1097/PGP.0000000000000512
8. Sato Y, Hida S, Inagaki M, Tsutsumi H, Hirota Y, Hongo J, et al. A Clinicopathologic Study of Endometrial Carcinomas with Argyrophil Cell. Acta Pathol Jpn. 1984 Nov;34(11):1669-1678.
9. Wiesel O, Kessous R, Dreiher J, Meirovitz M, Davidesko S, Samueli B, et al. Ambiguous high-grade endometrial carcinomas – an analysis of clinicopathologic factors and prognostic outcomes [Internet]. Int J Gynecol Cancer. 2023 Sep;33(Suppl 3):A151. Available from: https://dx.doi.org/10.1136/ijgc-2023-esgo.311
10. Nieberg RK, Hirschowitz S. Malignant endometrial pathology. Curr Opin Obstet Gynecol. 1992 Aug;4(4):492-497.